ReviewFrontiers in cardiovascular medicine2018
Multicellular Interactions in 3D Engineered Myocardial Tissue.
Review in Frontiers in cardiovascular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Extracellular Vesicles in Cardiac Cell Crosstalk: from Intercellular Communication to Clinical Translation.Cardiovascular drugs and therapy · 2026Review
- Electrically conductive biopolymer-based hydrogels and fibrous materials fabricated using 3D printing and electrospinning for cardiac tissue engineering.Bioactive materials · 2025Review
- Bioprinting approaches in cardiac tissue engineering to reproduce blood-pumping heart function.iScience · 2025Review
- Enhanced Maturation of 3D Bioprinted Skeletal Muscle Tissue Constructs Encapsulating Soluble Factor-Releasing Microparticles.Macromolecular bioscience · 2023Article
- Out of Box Thinking to Tangible Science: A Benchmark History of 3D Bio-Printing in Regenerative Medicine and Tissues Engineering.Life (Basel, Switzerland) · 2023Review
- Advances in 3D Organoid Models for Stem Cell-Based Cardiac Regeneration.International journal of molecular sciences · 2023Review
- Design and Fabrication of Mature Engineered Pre-Cardiac Tissue Utilizing 3D Bioprinting Technology and Enzymatically Crosslinking Hydrogel.Materials (Basel, Switzerland) · 2022Article
- Engineering Spatiotemporal Control in Vascularized Tissues.Bioengineering (Basel, Switzerland) · 2022Review
- Functional human cell-based vascularised cardiac tissue model for biomedical research and testing.Scientific reports · 2022Article
- Is a Bioengineered Heart From Recipient Tissues the Answer to the Shortage of Donors in Heart Transplantation?Cureus · 2022Review
- Engineering Three-Dimensional Vascularized Cardiac Tissues.Tissue engineering. Part B, Reviews · 2022Review
- Organ-on-a-chip systems for vascular biology.Journal of molecular and cellular cardiology · 2021Review
- Engineered cardiac tissues: a novel in vitro model to investigate the pathophysiology of mouse diabetic cardiomyopathy.Acta pharmacologica Sinica · 2021Article
- Development of a drug screening system using three-dimensional cardiac tissues containing multiple cell types.Scientific reports · 2021Article
- Engineering Cardiovascular Tissue Chips for Disease Modeling and Drug Screening Applications.Frontiers in bioengineering and biotechnology · 2021Review
- Human Cell Modeling for Cardiovascular Diseases.International journal of molecular sciences · 2020Review
- Cell spheroid fusion: beyond liquid drops model.Scientific reports · 2020Article
- Human pluripotent stem cell-derived cardiomyocytes for studying energy metabolism.Biochimica et biophysica acta. Molecular cell research · 2020Review
- Endothelial heterogeneity across distinct vascular beds during homeostasis and inflammation.eLife · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Cardiovascular disease is a leading cause of death in the US and many countries worldwide. Current cell-based clinical trials to restore cardiomyocyte (CM) health by local delivery of cells have shown only moderate benefit in improving cardiac pumping capacity. CMs have highly organized physiological structure and interact dynamically with non-CM populations, including endothelial cells and fibroblasts. Within engineered myocardial tissue, non-CM populations play an important role in CM survival and function, in part by secreting paracrine factors and cell-cell interactions. In this review, we summarize the progress of engineering myocardial tissue with pre-formed physiological multicellular organization, and present the challenges toward clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.